Earnings Summary

Halozyme Therapeutics, Inc.’s revenue jumped 4.67% since last year same period to $231.35Mn in the Q2 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 18.11% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 24.74% since last year same period to $93.25Mn in the Q2 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 21.38% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 19.17% since last year same period to 40.3% in the Q2 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 2.77% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.98 - a 28.95% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.98.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 22.97% since last year same period to 0.91 in the Q2 2024. This indicates that the Halozyme Therapeutics, Inc. has generated 22.97% annual rate of jump in its earning per share (EPS) in the last 4 quarters.